Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Starling OncologySTLN +5.56%56 EBITDA Margin % is 0.72% as of Mar. 2026. GuruFocus rates STLN with a GF Score™ of 56/100 and a GF Value™ of $2.29 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 662 Healthcare Providers & Services companies, Starling Oncology ranks worse than 78.85% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Starling Oncology's EBITDA for the
three
months ended in Mar. 2026 was $1.1 Mil. Starling Oncology's Revenue for the
three
months ended in Mar. 2026 was $147.4 Mil. Therefore, Starling Oncology's EBITDA margin for the quarter that ended in Mar. 2026 was 0.72%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Starling Oncology EBITDA Margin % Related Terms
Starling Oncology EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Starling Oncology's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STLN vs SRTA, CCRN, CYH: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Starling Oncology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Starling Oncology EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Starling Oncology's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Starling Oncology's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Starling Oncology (STLN) has a EBITDA Margin % of 0.72% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Starling Oncology and its competitors. According to the industry distribution chart, Starling Oncology ranks #522 out of 662 companies in the Healthcare Providers & Services industry, placing it in the top 78.9%.
Is Starling Oncology's EBITDA Margin % too high?
Starling Oncology's current EBITDA Margin % is 0.72%. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Starling Oncology's value of 0.72% is 92.9% below this industry median. Based on the distribution chart, Starling Oncology ranks #522 out of 662 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Starling Oncology has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starling Oncology's EBITDA Margin % compare to SRTA and CCRN?
According to the Healthcare Providers & Services industry distribution chart, Starling Oncology ranks #522 out of 662 companies for EBITDA Margin %. This places Starling Oncology in the lower half of its industry. The industry median EBITDA Margin % is 10.21. Starling Oncology's value of 0.72% is 92.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Starling Oncology's current EBITDA Margin % of 0.72% is 92.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Starling Oncology and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Starling Oncology's current EBITDA Margin % is 0.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starling Oncology stock overvalued right now?
Based on GuruFocus' analysis, Starling Oncology (STLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.29, compared to a current price of $5.17 — trading 125.8% above its estimated fair value. The current EBITDA Margin % is 0.72% and 92.9% below the Healthcare Providers & Services industry median of 10.21. Starling Oncology's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Starling Oncology (STLN), the current EBITDA Margin % is 0.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Starling Oncology (STLN) Overvalued in 2026?
Based on GuruFocus' analysis, Starling Oncology stock appears to be overvalued.
The current stock price of $5.17 is trading 125.8% above its estimated GF Value™ of $2.29.
GuruFocus considers Starling Oncology to be Significantly Overvalued.
Key valuation signals for STLN:
EBITDA Margin %: 0.72%
GF Value™: $2.29 vs. price of $5.17 (125.8% above fair value)
Industry Position: 92.9% below the Healthcare Providers & Services median (#522 of 662)
No single metric tells the full story. See the STLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score
Get the complete analysis for STLN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STLN has been successfully added to your 
